Projekt

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Abgeschlossen · 2020 bis 2024

Jörger Markus, Demmer-Steingruber Ruth, Quinter Janine